Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Torrent Pharmaceuticals Ltd.

http://www.torrentpharma.com

Latest From Torrent Pharmaceuticals Ltd.

Five Big Pharma Products That Saw Action In India; There’s More To Come

Scrip spotlights the action around five key big pharma products in India. We track the gains made by Rybelsus and Keytruda, the wave of Januvia and Ibrance generics and on-market and court action for blockbuster Entresto.

Commercial India

India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023

Commercial Scrip Perspectives

Entresto Patent Order Quashed In India, Market Ripe For Action

Court sets aside order pertaining to patent for Novartis’s Entresto in India, setting the stage for high-octane generic competition that potentially includes frontline domestic companies. If the Swiss firm appeals, market dynamics may be impacted but prices of same-composition second brands of the heart-failure therapy are already headed southwards.

Intellectual Property Legal Issues

Entresto Patent Order Quashed In India, Market Ripe For Action

Court sets aside order pertaining to patent for Novartis’s Entresto in India, setting the stage for high-octane generic competition that potentially includes frontline domestic companies. If the Swiss firm appeals, market dynamics may be impacted but prices of same-composition second brands of the heart-failure therapy are already headed southwards.

Commercial Intellectual Property
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Unichem Laboratories Ltd.
    • Bio-Pharm, Inc.
UsernamePublicRestriction

Register